Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Phosphorylation01:02

Phosphorylation

50.3K
The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
50.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Amyloid Fibrils03:03

Amyloid Fibrils

9.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: ETV6 c.744del gene mutation acute lymphoblastic leukemia in identical twins.

Frontiers in pediatrics·2026
Same author

Self-compassion and self-concept clarity mediated by resilience: variable-centered and person-centered approaches.

Frontiers in psychology·2026
Same author

Molecularly imprinted polymer wearable biosensing of cortisol in sweat for mental stress evaluation.

Talanta·2026
Same author

YTHDF1 impacts cardiomyocyte differentiation by regulating the TET2 mRNA.

PloS one·2026
Same author

Corrigendum to "Antibody-drug conjugates in oncology: A spotlight on overcoming resistance" [Crit. Rev. Oncol. Hematol. 217 (2026) 105015].

Critical reviews in oncology/hematology·2026
Same author

Case Report: Diagnosis and management of primary malignant melanoma of the bladder: a case-based review.

Frontiers in oncology·2026
Same journal

The Role of Digital Health Technologies in Early Detection and Management of Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Quantifying Short-Term Functional Changes After Lecanemab Treatment in Early Alzheimer's Disease: An Exploratory 3-Month Follow-Up Case Report Using Eye Movement and Gait Analysis.

Current Alzheimer research·2026
Same journal

Corrigendum to: Advancing Alzheimer's Disease Diagnosis Using VGG19 and XGBoost: A Neuroimaging-Based Method.

Current Alzheimer research·2026
Same journal

Corrigendum to: Lithium Chloride Improves Electrophysiological and Memory Deficits in Rats with Streptozotocin-Induced Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Apolipoprotein E Mimetics in Targeted Drug Delivery: Advances and Therapeutic Potential for Neurodegenerative and Cardiovascular Diseases.

Current Alzheimer research·2026
Same journal

Association of Polymorphisms in Genes Involved in Serotonergic Signaling with the Risk of Developing Alzheimer's Disease.

Current Alzheimer research·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2025

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.9K

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology.

Subha Kalyaanamoorthy1, Stanley Kojo Opare1, Xiaoxiao Xu1

  • 1Department of Chemistry, University of Waterloo, Waterloo, Ontario, Canada.

Current Alzheimer Research
|April 16, 2024
PubMed
Summary
This summary is machine-generated.

Tau protein modifications are key in Alzheimer

Keywords:
Alzheimer’s diseaseacetylationcomputational modelingdeamidationglycationglycosylationmethylationnitrationphosphorylationpost-translational modificationssumoylationtau proteintherapeutic approaches.truncationubiquitination

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

Related Experiment Videos

Last Updated: Jun 28, 2025

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.9K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Microtubule-Associated Protein Tau (tau) aggregates in Alzheimer's disease (AD).
  • Tau protein undergoes extensive post-translational modifications (PTMs) affecting its function and aggregation.
  • The interplay between tau PTMs in AD pathology is not fully understood.

Purpose of the Study:

  • To review key tau PTMs and their connections in tau physiology and pathophysiology.
  • To explore computational modeling's role in understanding PTM impacts on tau.
  • To highlight tau PTM-based therapeutic strategies for AD.

Main Methods:

  • Literature review of tau post-translational modifications.
  • Analysis of computational modeling approaches for tau structure-function.
  • Survey of therapeutic strategies targeting tau PTMs.

Main Results:

  • Tau PTMs significantly influence protein structure, solubility, and aggregation.
  • Interactions between different PTMs are crucial for tau's role in AD.
  • Computational models provide insights into PTM-mediated functional changes.
  • Various therapeutic strategies targeting tau PTMs are under investigation.

Conclusions:

  • Understanding tau PTM interplay is vital for elucidating AD pathogenesis.
  • Computational methods are valuable tools for studying tau PTMs.
  • Targeting tau PTMs offers promising therapeutic avenues for Alzheimer's disease.